Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun;16(6):1121-7.
doi: 10.1158/1055-9965.EPI-06-1062.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition

Naomi E Allen  1 , Timothy J Key, Paul N Appleby, Ruth C Travis, Andrew W Roddam, Sabina Rinaldi, Lars Egevad, Sabine Rohrmann, Jakob Linseisen, Tobias Pischon, Heiner Boeing, Nina Føns Johnsen, Anne Tjønneland, Henning Grønbaek, Kim Overvad, Lambartus Kiemeney, H Bas Bueno-de-Mesquita, Sheila Bingham, Kay Tee Khaw, Rosario Tumino, Franco Berrino, Amalia Mattiello, Carlotta Sacerdote, Domenico Palli, José Ramón Quirós, Eva Ardanaz, Carmen Navarro, Nerea Larrañaga, Carlos Gonzalez, Maria-José Sanchez, Antonia Trichopoulou, Cryssoula Travezea, Dimitrios Trichopoulos, Mazda Jenab, Pietro Ferrari, Elio Riboli, Rudolf Kaaks
Affiliations

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition

Naomi E Allen et al. Cancer Epidemiol Biomarkers Prev. 2007 Jun.

Abstract

Background: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer.

Methods: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression.

Results: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; Ptrend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; Ptrend = 0.11) for IGF-I adjusted for IGFBP-3.

Conclusions: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.

PubMed Disclaimer

Publication types

Substances

LinkOut - more resources